ReviewFrontiers in endocrinology2021
NLRP3 Inflammasome: A New Target for Prevention and Control of Osteoporosis?
Review in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it, 136 citations in OpenAlex.
- From mechanisms to therapeutics: a narrative review on pyroptosis and autophagy in osteoporosis.Annals of medicine · 2025Pooled it
- Bone targeted microenvironment actuated engineered exosomes for precision therapy of IBD associated bone loss.Bioactive materials · 2026Article
- Blockade of NLRP3 alleviates systemic lupus erythematosus-induced osteoporosis through dual modulation of osteogenesis and osteoclastogenesis.Bone reports · 2026Article
- BMP2-Binding Caffeoylquinic Acids fromBiology · 2026Article
- Role of epigallocatechin gallate on aluminum exposure-induced bone damage via NLRP3 inflammasome signaling pathway.Molecular biology reports · 2026Article
- The gut-bone axis: impact of diet on gut microbiome and osteoporosis.Bone research · 2026Review
- Targeting MDK alleviates bone loss via dual regulation of osteogenic differentiation and inflammatory cytokine expression.Genes & diseases · 2026Article
- Non-pyroptotic caspase-11 activity regulates osteoclastogenesis and pathological bone loss.Cell death and differentiation · 2026Article
- Mechanosensitive ion channels as novel targets in osteoporosis.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026Review
- Traditional Chinese Medicine for osteoporosis management: from molecular mechanisms to drug discovery.Chinese medicine · 2026Review
- Isoforskolin inhibits LUBAC/GSDMD/IL-1β cascades in pulmonary fibrosis.Journal of thoracic disease · 2026Article
- Inflammasome expression patterns during bone regeneration: predictive biomarkers and potential therapeutic targets in non-union formation.Frontiers in immunology · 2026Article
- Low-inflammatory macrophage-BMSC crosstalk enhances osteogenesis with attenuation of oxidative stress.American journal of clinical and experimental immunology · 2026Article
- Physical exercise therapy as an anti-aging strategy for osteosarcopenia: a narrative review.Frontiers in aging · 2026Review
- Article
- Polyphenols and Bone Health: A Comprehensive Review of Their Role in Osteoporosis Prevention and Treatment.Molecules (Basel, Switzerland) · 2025Review
- Causal effects and mediation pathways of circulating plasma proteins on osteoporosis: a two-sample and two-step Mendelian randomization study.Clinical proteomics · 2025Article
- High-fat diet, intestinal microecology and bone loss.Nutrition & metabolism · 2025Review
- Repeated exposure to CoCr28Mo6 particles leads to activation of NLRP3 inflammasome signaling in human osteoblasts.Cell biology and toxicology · 2025Article
- Kerala Ayurveda Ostoact Tablet treats osteoporosis in ovariectomized rat model via regulating RANKL/OPG pathway.Journal of traditional and complementary medicine · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a systemic bone metabolism disease that often causes complications, such as fractures, and increases the risk of death. The nucleotide-binding oligomerization domain-like-receptor family pyrin domain-containing 3 (NLRP3) inflammasome is an intracellular multiprotein complex that regulates the maturation and secretion of Caspase-1 dependent proinflammatory cytokines interleukin (IL)-1β and IL-18, mediates inflammation, and induces pyroptosis. The chronic inflammatory microenvironment induced by aging or estrogen deficiency activates the NLRP3 inflammasome, promotes inflammatory factor production, and enhances the inflammatory response. We summarize the related research and demonstrate that the NLRP3 inflammasome plays a vital role in the pathogenesis of osteoporosis by affecting the differentiation of osteoblasts and osteoclasts. IL-1β and IL-18 can accelerate osteoclast differentiation by expanding inflammatory response, and can also inhibit the expression of osteogenic related proteins or transcription factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.